Paul K. Paik, MD | Authors


VISION Trial Demonstrates Liquid Biopsy Is Comparable to Tissue Biopsy for NSCLC

June 20, 2019

Paul K. Paik, MD, discusses the benefits to using liquid biopsy compared to a tissue biopsy, particularly in the phase II VISION trial in which patients with non–small cell lung cancer harboring MET alterations were treated with tepotinib. Patients were divided into 2 cohorts based on whether they were enrolled with either a liquid biopsy or tumor biopsy.

Advances in the Treatment of Squamous Cell Lung Cancer

January 13, 2018

Paul K. Paik, MD, clinical director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses recent chemotherapy and immunotherapy advances in the treatment of squamous cell lung cancer.